Director
Eli Lilly and Company
Indianapolis, Indiana
Wendy Q. Yang is a Director of Analytical Quality Control Operations at Eli Lilly and Company, bringing over 34 years of expertise in analytical method development and validation across the pharmaceutical industry. With a Master of Science in Analytical Chemistry from Nankai University in China, she has built an exceptional career spanning both global pharmaceutical companies and regulatory bodies.
At Lilly since 2002, Wendy has served as the analytical steward for major therapies including Retartrutide (diabetes), Selpercatinib (oncology), Baricitinib (rheumatoid arthritis), and Pemetrexed (oncology). She has led analytical method installations across Lilly's global testing network and supported more than 20 regulatory submissions worldwide, achieving successful approvals for products including Retevmo, Olumiant, and Alimta.
A recognized leader in innovation, Wendy spearheaded the Global Method Package Initiative, which standardized analytical practice across Lilly’s global testing sites. She has also influenced international regulatory policy through participation in ICH Q3C and Q3D Industry Advisory Committees in China. Her expertise spans HPLC, GC, LC/MS, NIR-based real-time release testing, and container closure integrity, with deep knowledge of global compliance standards including ICH, USP, PhEur, and JP.
Disclosure information not submitted.
Analytical Method Standardization- An Initiative for Quality, Efficiency, and Harmonization
Wednesday, July 15, 2026
8:35 AM - 9:05 AM East Coast USA Time